Market revenue in 2023 | USD 34.9 million |
Market revenue in 2030 | USD 39.5 million |
Growth rate | 1.8% (CAGR from 2023 to 2030) |
Largest segment | Immunosuppressants |
Fastest growing segment | Immunosuppressants |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Immunosuppressants |
Key market players worldwide | Bristol-Myers Squibb Co, Celgene, Eisai Co Ltd, Phaxiam, Roche Holding AG, Genmab A/S, GlaxoSmithKline, Novartis AG ADR, Pfizer Inc, Sanofi SA |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account